Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis

June 2, 2026 06:58 AM EDT R&D Can­cer cas­es weigh down Abi­vax’s Phase 3 main­te­nance da­ta in ul­cer­a­tive col­i­tis Reynald Castaneda Deputy Editor Abi­vax has pro­claimed that its main­te­nance tri­al in ul­cer­a­tive col­i­tis de­liv­ered “land­mark” re­sults, and the drug’s safe­ty pro­file has pre­vi­ous­ly been one of its main … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER